Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion

(TheNewswire)

Calgary, AB – November 7, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developerof pharmaceutical-grade barium and iodine for medical imaging contrastmedia, is pleased to announce, subject to regulatory approval, theappointment of Virginia Alling as an independent director. Thisaddition builds on the Company’s recent board enhancements with WallStreet veterans Jeffrey J. Kraws and Christopher A. Van Buren, furtherpositioning Voyageur for accelerated U.S. capital market access andstrategic growth.

Ms. Alling brings over 30 years of experience incorporate banking, capital markets, and strategic advisory for bothprivately held and publicly traded companies. As Senior Vice President& Managing Director at PNC Bank in East Brunswick, NJ, she managesa multi-billion-dollar portfolio of corporate clients in New Jerseyand New York, including M&A, IPOs, ESOPs, leveraged finance, andrevenue optimization. Her expertise includes guiding privateequity-backed and multigenerational family-owned businesses throughcapital structure solutions, succession planning, and risk management.Previously, Ms. Alling served as Vice President in Corporate Finance& Corporate Banking at JPMorgan Chase (formerly known as ChemicalBank) in New Jersey and Assistant Vice President at Wells Fargo(formerly CoreStates) in Philadelphia. A Registered Investment Adviser(RIA) with FINRA Series 7 & 63 licenses, she holds an MBA from theRaymond A. Mason School of Business at the College of William &Mary. Ms. Alling is also an active board member and nonprofit leader,with a strong commitment to advancing technology, healthcare, andphilanthropy.

“We are thrilled to welcome Virginia Alling to ourboard,” said Brent Willis, Voyageur’s CEO. “Her excellent trackrecord in executing U.S. public offerings, revenue optimization, andcross-border financing complements our recent appointments of JeffreyKraws and Christopher Van Buren. We believe that Virginia’s deepexperience in M&A and capital markets will be instrumental inunlocking institutional U.S. investment, streamlining our US marketentry, and ensuring robust governance as we scale our innovativebarium and iodine pipeline for North American healthcare providers.Her expertise in family-owned enterprises and strategic partnershipsaligns well with Voyageur’s vision of sustainable growth and valuecreation for shareholders.”

The appointments of Ms. Alling, Mr. Kraws, and Mr. VanBuren underscore Voyageur’s commitment to assembling a high-calibreboard with proven Wall Street acumen to facilitate U.S. marketexpansion. Their collective experience in revenue generation, IPOexecution, and regulatory compliance should support Voyageur’scommercialization efforts, including FDA approvals for its bariumcontrast products and scaling of its Oklahoma iodineoperations.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the on the TSX Venture Exchange, is in development ofbarium and iodine Active Pharmaceutical Ingredients (API) that offerhigh-performance and cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium and iodinecontrast markets, Voyageur aims to become a key player by producingits own barium and iodine. In addition, Voyageur is pursuing thedevelopment of new endo fullerene drugs.

Voyageur's business plan is set to generate salesby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada thereby ensuring the validation of itsproducts by regulatory agencies worldwide. As Voyageur solidifies itspresence in the market, it plans to transition into a high-margindomestic manufacturer of radiology drugs.

At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project.Currently, the world’s pharmaceutical barium sulphate is almostentirely synthetically produced resulting in a less effective imagingquality product. Voyageur’s Frances Creek resource boasts a rare andexceptional grade mineral suitable for the pharmaceutical marketplacethat Voyageur believes will replace the current synthetic productswith higher quality imaging products.

Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to final production, Voyageur believes it can ensurequality and cost efficiency. With its approach, it embodies the mottoof " From the Earth to theBottle ," highlighting Voyageur'scommitment to responsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

This news release may containcertain forward-looking information and statements, including withoutlimitation, statements pertaining to: the Company obtaining allrequired regulatory approvals for the appointment of the new director;the Company's beliefs regarding the anticipated benefits to bederived from Ms. Alling's experience in M&A and capitalmarkets; the Company's expectation that the collective experienceof Mr. Kraws, Mr. van Buren and Ms. Alling will support Voyageur’scommercialization efforts; the Company's expectation regardingthe benefits of its vertically integrated model; the Company'splans to expand its US operations over the course of the followingmonths and years; the Company's aim to become a key player in thebarium and iodine contrast markets; the Company's plans totransition into a high-margin domestic manufacturer of radiologydrugs; the Company'sbelief that the Frances Creek Project's mineral will replace thecurrent synthetic products in the pharmaceutical marketplace withhigher quality imaging products; and the Company's belief that itcan ensure quality and cost efficiency by controlling all primaryinput costs. All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents onthe SEDAR+ website at www.sedarplus.ca. Voyageur does not undertake toupdate any forward-looking information except in accordance withapplicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.